{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:11Z","timestamp":1791910811358,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Municipal Commission of Health and Family Planning","award":["(No.201440019"],"award-info":[{"award-number":["(No.201440019"]}]},{"name":"The National Key Research and Development Program of China","award":["No.2016YFC0901504"],"award-info":[{"award-number":["No.2016YFC0901504"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00415-017-8616-7","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T05:04:11Z","timestamp":1505711051000},"page":"2191-2200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"264","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"issue":"7","key":"8616_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 16(7):459\u2013467. doi:\n                        10.1016\/j.nmd.2006.05.006","journal-title":"Neuromuscul Disord"},{"key":"8616_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cca.2015.01.042","volume":"444","author":"J Oger","year":"2015","unstructured":"Oger J, Frykman H (2015) An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta 444:126\u2013131. doi:\n                        10.1016\/j.cca.2015.01.042","journal-title":"Clin Chim Acta"},{"issue":"6","key":"8616_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","volume":"6","author":"M Garcia-Carrasco","year":"2007","unstructured":"Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R (2007) Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 6(6):373\u2013378. doi:\n                        10.1016\/j.autrev.2007.01.001","journal-title":"Autoimmun Rev"},{"issue":"5","key":"8616_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475\u2013490. doi:\n                        10.1016\/s1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"8616_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN (2015) The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord 8(2):92\u2013103. doi:\n                        10.1177\/1756285615571873","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"8616_CR6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 40(9):1256\u20131265","journal-title":"J Antibiot"},{"issue":"4","key":"8616_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-j","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13(4):136\u2013142. doi:\n                        10.1016\/0167-5699(92)90111-j","journal-title":"Immunol Today"},{"issue":"3","key":"8616_CR8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","volume":"64","author":"AD Mayer","year":"1997","unstructured":"Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64(3):436\u2013443","journal-title":"Transplantation"},{"issue":"7","key":"8616_CR9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","volume":"63","author":"JD Pirsch","year":"1997","unstructured":"Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63(7):977\u2013983","journal-title":"Transplantation"},{"issue":"1\u20132","key":"8616_CR10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0041-1345(00)02312-5","volume":"33","author":"F Vincenti","year":"2001","unstructured":"Vincenti F (2001) Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 33(1\u20132):1019\u20131020","journal-title":"Transplant Proc"},{"issue":"9166","key":"8616_CR11","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/s0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet (London, England) 353(9166):1762\u20131763. doi:\n                        10.1016\/s0140-6736(99)01927-3","journal-title":"Lancet (London, England)"},{"issue":"20","key":"8616_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/nejm199605163342002","volume":"334","author":"JR O\u2019Dell","year":"1996","unstructured":"O\u2019Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334(20):1287\u20131291. doi:\n                        10.1056\/nejm199605163342002","journal-title":"N Engl J Med"},{"issue":"11","key":"8616_CR13","first-page":"2332","volume":"26","author":"RB Gremillion","year":"1999","unstructured":"Gremillion RB, Posever JO, Manek N, West JP, van Volen-Hoven RF (1999) Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 26(11):2332\u20132336","journal-title":"J Rheumatol"},{"issue":"11","key":"8616_CR14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/ard.56.11.690","volume":"56","author":"M Duddridge","year":"1997","unstructured":"Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56(11):690\u2013692","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8616_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/berh.2001.0227","volume":"16","author":"MA Solsky","year":"2002","unstructured":"Solsky MA, Wallace DJ (2002) New therapies in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16(2):293\u2013312. doi:\n                        10.1053\/berh.2001.0227","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"8616_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S (2008) Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 4(6):317\u2013327. doi:\n                        10.1038\/ncpneuro0810","journal-title":"Nat Clin Pract Neurol"},{"issue":"2","key":"8616_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10072-016-2769-5","volume":"38","author":"X Tao","year":"2017","unstructured":"Tao X, Wang W, Jing F, Wang Z, Chen Y, Wei D, Huang X (2017) Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis. Neurol Sci 38(2):325\u2013330. doi:\n                        10.1007\/s10072-016-2769-5","journal-title":"Neurol Sci"},{"issue":"8","key":"8616_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079904125004385","volume":"20","author":"N Kawaguchi","year":"2004","unstructured":"Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T (2004) Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20(8):1269\u20131273. doi:\n                        10.1185\/030079904125004385","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"8616_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","volume":"76","author":"T Konishi","year":"2005","unstructured":"Konishi T, Yoshiyama Y, Takamori M, Saida T (2005) Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 76(3):448\u2013450. doi:\n                        10.1136\/jnnp.2004.042176","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"8616_CR20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1212\/01.wnl.0000160392.32894.6d","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Cervera C, Armengol M (2005) Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64(9):1641\u20131643. doi:\n                        10.1212\/01.wnl.0000160392.32894.6d","journal-title":"Neurology"},{"issue":"3","key":"8616_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","volume":"107","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M (2005) Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 107(3):187\u2013190. doi:\n                        10.1016\/j.clineuro.2004.07.013","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"8616_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","volume":"11","author":"CB Zhao","year":"2011","unstructured":"Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, Xiao BG (2011) Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11(4):519\u2013524. doi:\n                        10.1016\/j.intimp.2010.12.012","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"8616_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y (2005) Efficacy of low-dose FK506 in the treatment of Myasthenia gravis\u2014a randomized pilot study. Eur Neurol 53(3):146\u2013150. doi:\n                        10.1159\/000085833","journal-title":"Eur Neurol"},{"issue":"6","key":"8616_CR24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1054\/jocn.2001.0907","volume":"9","author":"H Yoshikawa","year":"2002","unstructured":"Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M (2002) Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 9(6):627\u2013628","journal-title":"J Clin Neurosci"},{"issue":"1","key":"8616_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","volume":"106","author":"N Wakata","year":"2003","unstructured":"Wakata N, Saito T, Tanaka S, Hirano T, Oka K (2003) Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 106(1):5\u20138","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"8616_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.10472","volume":"28","author":"T Konishi","year":"2003","unstructured":"Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T (2003) Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 28(5):570\u2013574. doi:\n                        10.1002\/mus.10472","journal-title":"Muscle Nerve"},{"issue":"1","key":"8616_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","volume":"25","author":"A Evoli","year":"2002","unstructured":"Evoli A, Di Schino C, Marsili F, Punzi C (2002) Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 25(1):111\u2013114","journal-title":"Muscle Nerve"},{"issue":"3","key":"8616_CR28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0025-7753(02)72301-4","volume":"118","author":"JM Ponseti","year":"2002","unstructured":"Ponseti JM, Fort JM, Espin E, Armengol M (2002) Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases. Med Clin 118(3):117","journal-title":"Med Clin"},{"issue":"1","key":"8616_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"key":"8616_CR30","unstructured":"Higgins JPT, Altman DG (2011) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. \n                        http:\/\/www.cochrane-handbook.org"},{"issue":"9","key":"8616_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M (2011) Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82(9):970\u2013977. doi:\n                        10.1136\/jnnp-2011-300148","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"8616_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu WB, Li HF, Zhang X, Shang HF, Zhang X, Bu BT, Deng H, Fang Q, Li JM, Zhang H, Song Z, Ou CY, Yan CZ, Liu T, Zhou HY, Bao JH, Lu JH, Shi HW, Zhao CB (2017) Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord 10(9):315\u2013325. doi:\n                        10.1177\/1756285617721092","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"8616_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079907x188080","volume":"23","author":"JM Ponseti","year":"2007","unstructured":"Ponseti JM, Gamez J, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Armengol M (2007) Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. Curr Med Res Opin 23(6):1269\u20131278. doi:\n                        10.1185\/030079907x188080","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"8616_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cen3.12188","volume":"6","author":"K Utsugisawa","year":"2015","unstructured":"Utsugisawa K, Nagane Y, Imai T, Motomura M, Masuda M, Konno S, Suzuki S (2015) Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: a retrospective analysis of outcomes. Clin Exp Neuroimmunol 6(2):195\u2013200. doi:\n                        10.1111\/cen3.12188","journal-title":"Clin Exp Neuroimmunol"},{"issue":"2","key":"8616_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000062987","volume":"48","author":"R Munakata","year":"2002","unstructured":"Munakata R, Utsugisawa K, Nagane Y, Yamagata M, Oikawa M, Obara D, Tohgi H (2002) The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis. Eur Neurol 48(2):115\u2013117","journal-title":"Eur Neurol"},{"issue":"1","key":"8616_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","volume":"247","author":"M Tada","year":"2006","unstructured":"Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, Naruse S, Tanaka K, Tsuji S, Nishizawa M (2006) Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 247(1):17\u201320. doi:\n                        10.1016\/j.jns.2006.03.010","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"8616_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","volume":"195","author":"Y Furukawa","year":"2008","unstructured":"Furukawa Y, Yoshikawa H, Iwasa K, Yamada M (2008) Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 195(1\u20132):108\u2013115. doi:\n                        10.1016\/j.jneuroim.2007.12.008","journal-title":"J Neuroimmunol"},{"key":"8616_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M (2008) Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci 1132:254\u2013263. doi:\n                        10.1196\/annals.1405.000","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"8616_CR39","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","volume":"62","author":"M Takamori","year":"2004","unstructured":"Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yoshikawa H, Otsuka K (2004) Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62(10):1894\u20131896","journal-title":"Neurology"},{"issue":"2","key":"8616_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/01.nrl.0000256352.77668.ef","volume":"13","author":"T Mitsui","year":"2007","unstructured":"Mitsui T, Kunishige M, Ichimiya M, Shichijo K, Endo I, Matsumoto T (2007) Beneficial effect of tacrolimus on myasthenia gravis with thymoma. Neurologist 13(2):83\u201386. doi:\n                        10.1097\/01.nrl.0000256352.77668.ef","journal-title":"Neurologist"},{"issue":"2","key":"8616_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.21462","volume":"41","author":"Y Nagane","year":"2010","unstructured":"Nagane Y, Suzuki S, Suzuki N, Utsugisawa K (2010) Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 41(2):212\u2013218. doi:\n                        10.1002\/mus.21462","journal-title":"Muscle Nerve"},{"issue":"2","key":"8616_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mus.10285","volume":"27","author":"K Utsugisawa","year":"2003","unstructured":"Utsugisawa K, Nagane Y, Yonezawa H, Obara D, Kondoh R, Tohgi H (2003) Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve 27(2):245\u2013248. doi:\n                        10.1002\/mus.10285","journal-title":"Muscle Nerve"},{"issue":"3","key":"8616_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI (2012) Myasthenia gravis. Semin Neurol 32(3):215\u2013226. doi:\n                        10.1055\/s-0032-1329200","journal-title":"Semin Neurol"},{"issue":"1\u20132","key":"8616_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","volume":"300","author":"N Minami","year":"2011","unstructured":"Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, Sasaki H (2011) Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 300(1\u20132):59\u201362. doi:\n                        10.1016\/j.jns.2010.09.033","journal-title":"J Neurol Sci"},{"issue":"5","key":"8616_CR45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0952-7915(93)90135-F","volume":"5","author":"BE Bierer","year":"1993","unstructured":"Bierer BE, Hollander G, Fruman D, Burakoff SJ (1993) Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5(5):763\u2013773","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"8616_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","volume":"24","author":"T Kanai","year":"2017","unstructured":"Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, Kuwabara S (2017) Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol 24(2):270\u2013275. doi:\n                        10.1111\/ene.13189","journal-title":"Eur J Neurol"},{"issue":"6","key":"8616_CR47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/TP.0b013e3182461288","volume":"93","author":"PA Jacobson","year":"2012","unstructured":"Jacobson PA, Schladt D, Israni A, Oetting WS, Lin YC, Leduc R, Guan W, Lamba V, Matas AJ (2012) Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation 93(6):624\u2013631. doi:\n                        10.1097\/TP.0b013e3182461288","journal-title":"Transplantation"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8616-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T13:15:35Z","timestamp":1508937335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8616-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["8616"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8616-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}